Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

William Richardson

Family Medicine Vernon, NY Medical Doctor

NPI 1457409617 CMS profile 247769

3 Curtis Road, Trivalley Family Practice LLC, Vernon, NY 13476

Open in the dashboard

General payments

$84

4 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Richardson of Vernon, NY is reported in the CMS Open Payments database as having received $84 across 4 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 27th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $64 3
2022 General $20 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Richardson
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to William Richardson were reported at $64. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year William Richardson Family Medicine median Middle half National median
2019 $0 $150 $41–$543 $163
2020 $0 $120 $32–$415 $114
2021 $0 $137 $35–$551 $132
2022 $20 $137 $37–$512 $149
2023 $0 $149 $42–$545 $160
2024 $0 $156 $44–$560 $164
2025 $64 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $32 1 payment
  2. AstraZeneca Pharmaceuticals LP $32 2 payments
  3. Sunovion Pharmaceuticals Inc. $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $84 4 payments
Products named General payments · program years 2022–2025
  1. VRAYLAR $32 1 payment
  2. BREZTRI $32 2 payments
  3. APTIOM $20 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 176 drugs

Part D claims

16,101

Median for Family Practice: 1,826

Drug cost

$1,004,630

Median for Family Practice: $120,094

Branded share of claims

23.7%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 707 $154,904
Tetrabenazine Generic 14 $83,955
Nuplazid Pimavanserin Tartrate Brand 30 $70,441
Dimethyl Fumarate Generic 13 $68,654
Trulicity Dulaglutide Brand 103 $66,259
Nuedexta Dextromethorphan Hbr/Quinidine Brand 84 $58,258
Xarelto Rivaroxaban Brand 202 $42,473
Rexulti Brexpiprazole Brand 84 $42,173
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 50 $32,384
Xofluza Baloxavir Marboxil Brand 103 $18,047

The 10 drugs with the highest cost, of 176 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$84,311

Medicare's payments for the services billed

Medicare patients

233

Average age 76

Services billed

896

134 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Alzheimer's or dementia 67%
Depression 52%
Chronic kidney disease 43%
Arthritis 43%
Diabetes 41%
Ischemic heart disease 39%
Heart failure 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

4 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record